Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Not applicable

Evaluation of Two Monthly Silicone Hydrogel Multifocal Toric in Soft Contact Lens Wearers

NCT07829419 · tracked via the Priya Life Science USA tracker
Phase
Not applicable
Started
2026-09
Last updated
2026-09-21

Condition(s) studied

AstigmatismMyopia

Investigational drug(s) / intervention(s)

Lens A ( comfilcon A)Lens B ( lehfilcon A)

Lens A ( comfilcon A): Daily disposable, soft contact lenses worn for one month

Lens B ( lehfilcon A): Daily disposable, soft contact lenses worn for one month

Study summary

To compare the performance of two leading soft multifocal Toric contact lenses.

Eligibility

Sex
ALL
Min age
40 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: A person is eligible for inclusion in the study if they are: 1. Participants at least 40 years of age. 2. Participants requiring lens powers within the range available for the study lenses. 3. Participants with a spherical refractive error at the corneal plane of plano to -6.00. 4. Participants with a minimum reading add of +0.75DS (based on their spectacle refraction at screening). At least 12 participants will be enrolled per add group: low (+0.75 to +1.25D), medium (+1.50 to +1.75D), and high (+2.00 to +2.50). 5. Participants with refractive astigmatism at the corneal plane of 0.75 to 2.00DC. 6. Best spectacle corrected visual acuity greater than or equal to 20/25 (less than or equal to LogMAR 0.1). 7. Habitually using soft contact lenses (multifocal soft contact lenses, sphere or toric lenses for monovision, or sphere or toric lenses for distance vision correction and spectacles for near vision correction) and have worn lenses at least 3 days a week for at least the past six months. 8. Anticipating being able to wear contact lenses for at least 8 hours a day, 5 days a week. 9. Willing and able to follow instructions and maintain the appointment schedule. Exclusion Criteria: 1. Anterior segment infection, inflammation or abnormality that would contraindicate contact lens wear. 2. Any active anterior segment ocular disease that would contraindicate contact lens wear. 3. The use of systemic or ocular medications that would contraindicate contact lens wear. 4. History of herpetic keratitis. 5. History of refractive surgery or irregular cornea. 6. Slit lamp findings that are more serious than grade 1 (see ISO 11980 scale). 7. Inactive (i.e. ghost) vessels greater than 1 mm of penetration into the cornea. 8. Participation of the participant in a contact lens or contact lens care product clinical trial within the previous 90 days if involving orthokeratology, 30 days if involving extended wear, rigid gas permeable corneal and scleral lenses, or 15 days if involving daily disposable, daily wear soft lenses.

Primary outcome measure(s)

  • Ease of handling — 1 month
    Ease of handling for lens removal (0-100)

Trial sites (3)

FacilityCityRegionStatus
Sacco Eye Group New York New York
ProCare Vision Center Granville Ohio
Drs. Mcintyre Garza Avila & Jurica Corpus Christi Texas

More CooperVision International Limited (CVIL) trials in the USA

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07829419 on ClinicalTrials.gov ↗ ← All trials in the USA